Literature DB >> 7691311

Refinement of the structure of human basic fibroblast growth factor at 1.6 A resolution and analysis of presumed heparin binding sites by selenate substitution.

A E Eriksson1, L S Cousens, B W Matthews.   

Abstract

The three-dimensional structure of human basic fibroblast growth factor has been refined to a crystallographic residual of 16.1% at 1.6 A resolution. The structure has a Kunitz-type fold and is composed of 12 antiparallel beta-strands, 6 of which form a beta-barrel. One bound sulfate ion has been identified in the model, hydrogen bonded to the side chains of Asn 27, Arg 120, and Lys 125. The side chain of Arg 120 has two conformations, both of which permit hydrogen bonds to the sulfate. This sulfate binding site has been suggested as the binding site for heparin (Eriksson, A.E., Cousens, L.S., Weaver, L.H., & Matthews, B.W., 1991, Proc. Natl. Acad. Sci. USA 88, 3441-3445). Two beta-mercaptoethanol (BME) molecules are also included in the model, each forming a disulfide bond to the S gamma atoms of Cys 69 and Cys 92, respectively. The side chain of Cys 92 has two conformations of which only one can bind BME. Therefore the BME molecule is half occupied at this site. The locations of possible sulfate binding sites on the protein were examined by replacing the ammonium sulfate in the crystallization medium with ammonium selenate. Diffraction data were measured to 2.2 A resolution and the structure refined to an R-factor of 13.8%. The binding of the more electron-dense selenate ion was identified at two positions. One position was identical to the sulfate binding site identified previously. The second selenate binding site, which is of lower occupancy, is situated 5.6 A from the first. This ion is hydrogen bonded by the side chain of Lys 135 and Arg 120. Thus the side chain of Arg 120 binds two selenate ions simultaneously. It is suggested that the observed second selenate binding site should also be considered as a possible binding site for heparin, or that both selenate binding sites might simultaneously contribute to the binding of heparin.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 7691311      PMCID: PMC2142437          DOI: 10.1002/pro.5560020810

Source DB:  PubMed          Journal:  Protein Sci        ISSN: 0961-8368            Impact factor:   6.725


  49 in total

1.  Primary structure of bovine pituitary basic fibroblast growth factor (FGF) and comparison with the amino-terminal sequence of bovine brain acidic FGF.

Authors:  F Esch; A Baird; N Ling; N Ueno; F Hill; L Denoroy; R Klepper; D Gospodarowicz; P Böhlen; R Guillemin
Journal:  Proc Natl Acad Sci U S A       Date:  1985-10       Impact factor: 11.205

2.  Crystal structure of the complex of porcine trypsin with soybean trypsin inhibitor (Kunitz) at 2.6-A resolution.

Authors:  R M Sweet; H T Wright; J Janin; C H Chothia; D M Blow
Journal:  Biochemistry       Date:  1974-09-24       Impact factor: 3.162

3.  Three-fold structural pattern in the soybean trypsin inhibitor (Kunitz).

Authors:  A D McLachlan
Journal:  J Mol Biol       Date:  1979-10-09       Impact factor: 5.469

4.  Dictionary of protein secondary structure: pattern recognition of hydrogen-bonded and geometrical features.

Authors:  W Kabsch; C Sander
Journal:  Biopolymers       Date:  1983-12       Impact factor: 2.505

5.  Conformation of amino acid side-chains in proteins.

Authors:  J Janin; S Wodak
Journal:  J Mol Biol       Date:  1978-11-05       Impact factor: 5.469

6.  Heparin binds endothelial cell growth factor, the principal endothelial cell mitogen in bovine brain.

Authors:  T Maciag; T Mehlman; R Friesel; A B Schreiber
Journal:  Science       Date:  1984-08-31       Impact factor: 47.728

7.  Human endothelial cells are chemotactic to endothelial cell growth factor and heparin.

Authors:  V P Terranova; R DiFlorio; R M Lyall; S Hic; R Friesel; T Maciag
Journal:  J Cell Biol       Date:  1985-12       Impact factor: 10.539

8.  Interaction of endothelial cell growth factor with heparin: characterization by receptor and antibody recognition.

Authors:  A B Schreiber; J Kenney; W J Kowalski; R Friesel; T Mehlman; T Maciag
Journal:  Proc Natl Acad Sci U S A       Date:  1985-09       Impact factor: 11.205

9.  Human endothelial cells: use of heparin in cloning and long-term serial cultivation.

Authors:  S C Thornton; S N Mueller; E M Levine
Journal:  Science       Date:  1983-11-11       Impact factor: 47.728

10.  Heparin affinity: purification of a tumor-derived capillary endothelial cell growth factor.

Authors:  Y Shing; J Folkman; R Sullivan; C Butterfield; J Murray; M Klagsbrun
Journal:  Science       Date:  1984-03-23       Impact factor: 47.728

View more
  15 in total

1.  Molecular characteristics of fibroblast growth factor-fibroblast growth factor receptor-heparin-like glycosaminoglycan complex.

Authors:  G Venkataraman; R Raman; V Sasisekharan; R Sasisekharan
Journal:  Proc Natl Acad Sci U S A       Date:  1999-03-30       Impact factor: 11.205

2.  Development of an in vivo method to identify mutants of phage T4 lysozyme of enhanced thermostability.

Authors:  P Pjura; M Matsumura; W A Baase; B W Matthews
Journal:  Protein Sci       Date:  1993-12       Impact factor: 6.725

3.  Gentisic acid, a compound associated with plant defense and a metabolite of aspirin, heads a new class of in vivo fibroblast growth factor inhibitors.

Authors:  Israel S Fernández; Pedro Cuevas; Javier Angulo; Pilar López-Navajas; Angeles Canales-Mayordomo; Rocío González-Corrochano; Rosa M Lozano; Serafín Valverde; Jesús Jiménez-Barbero; Antonio Romero; Guillermo Giménez-Gallego
Journal:  J Biol Chem       Date:  2010-02-09       Impact factor: 5.157

4.  Fibroblast growth factors 1 and 2 are distinct in oligomerization in the presence of heparin-like glycosaminoglycans.

Authors:  G Venkataraman; Z Shriver; J C Davis; R Sasisekharan
Journal:  Proc Natl Acad Sci U S A       Date:  1999-03-02       Impact factor: 11.205

5.  High throughput protein fold identification by using experimental constraints derived from intramolecular cross-links and mass spectrometry.

Authors:  M M Young; N Tang; J C Hempel; C M Oshiro; E W Taylor; I D Kuntz; B W Gibson; G Dollinger
Journal:  Proc Natl Acad Sci U S A       Date:  2000-05-23       Impact factor: 11.205

6.  Syndromic congenital sensorineural deafness, microtia and microdontia resulting from a novel homoallelic mutation in fibroblast growth factor 3 (FGF3).

Authors:  Osama Alsmadi; Brian F Meyer; Fowzan Alkuraya; Salma Wakil; Fadi Alkayal; Haya Al-Saud; Khushnooda Ramzan; MoeenAldeen Al-Sayed
Journal:  Eur J Hum Genet       Date:  2008-08-13       Impact factor: 4.246

7.  Heparin binding to platelet factor-4. An NMR and site-directed mutagenesis study: arginine residues are crucial for binding.

Authors:  K H Mayo; E Ilyina; V Roongta; M Dundas; J Joseph; C K Lai; T Maione; T J Daly
Journal:  Biochem J       Date:  1995-12-01       Impact factor: 3.857

8.  Major degradation products of basic fibroblast growth factor: detection of succinimide and iso-aspartate in place of aspartate.

Authors:  Z Shahrokh; G Eberlein; D Buckley; M V Paranandi; D W Aswad; P Stratton; R Mischak; Y J Wang
Journal:  Pharm Res       Date:  1994-07       Impact factor: 4.200

9.  Preferential self-association of basic fibroblast growth factor is stabilized by heparin during receptor dimerization and activation.

Authors:  G Venkataraman; V Sasisekharan; A B Herr; D M Ornitz; G Waksman; C L Cooney; R Langer; R Sasisekharan
Journal:  Proc Natl Acad Sci U S A       Date:  1996-01-23       Impact factor: 11.205

10.  Susceptibility towards intramolecular disulphide-bond formation affects conformational stability and folding of human basic fibroblast growth factor.

Authors:  D Estapé; J van den Heuvel; U Rinas
Journal:  Biochem J       Date:  1998-10-15       Impact factor: 3.857

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.